MTOR and non-small cell lung carcinoma: In summary, the current study has demonstrated that the combination of RAD001 and the PI3K/mTOR inhibitor BEZ235 exhibits synergistic inhibition on the growth of NSCLC cells in vitro and in vivo and thus represents a novel strategy to enhance the efficacy of mTOR-targeted cancer therapy.